Sparsentan for treating primary IgA nephropathy
Sparsentan is a dual endothelin angiotensin receptor antagonist developed for the treatment of IgA nephropathy (1).
NICE state that (2):
Sparsentan can be used as option to treat primary immunoglobulin A nephropathy (IgAN) in adults with a:
- urine protein excretion of 1.0 g/day or more, or
- urine protein-to-creatinine ratio (UPCR) of 0.75 g/g or more
Sparsentan should be stopped after 36 weeks if a person's UPCR:
- is 1.76 g/g or more and
- has not reduced by 20% or more since starting sparsentan
The NICE committee note that "...clinical trial evidence shows that sparsentan reduces UPCR more than irbesartan. Evidence also suggests that sparsentan is better at maintaining kidney function than irbesartan, but this is uncertain..."
Reference:
- Syed YY. Sparsentan: First Approval. Drugs. 2023 Apr;83(6):563-568.
- NICE (June 2025). Sparsentan for treating primary IgA nephropathy
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.